LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
23 funds hold it · Insiders net selling
Net selling: insiders sold $7.8M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.17 expected
Estimates as of Nov 9, 2026
EPS expected
$0.13 to $0.15
Revenue expected
13 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $0.61est. $0.17 | +$0.44beat | $357.8MSEC filing | +69.6%from $211.0M |
| Jun 30, 2026Reported Jul 30, 2026 | $0.92est. -$0.17 | +$1.09beat | $360.5MSEC filing | +101.5%from $178.9M |
| Mar 31, 2026Reported May 7, 2026 | -$0.03est. -$0.44 | +93.18%beat | $272.6MSEC filing | -76.8%from $1.18B |
| Dec 31, 2025Reported Feb 19, 2026 | -$1.80est. -$0.40 | -$1.40miss | $164.7MAlpha Vantage | -22.7%from $213.2M |
| Sep 30, 2025Reported Nov 4, 2025 | $0.19est. -$1.11 | +117.12%beat | $211.0MSEC filing | +7.2%from $196.8M |
| Jun 30, 2025Reported Aug 7, 2025 | -$0.83est. -$1.07 | +22.43%beat | $178.9MSEC filing | -4.2%from $186.7M |
| Mar 31, 2025Reported May 6, 2025 | $10.04est. -$0.70 | +$10.74beat | $1.18BSEC filing | +459.7%from $210.1M |
| Dec 31, 2024Reported Feb 27, 2025 | -$0.34est. -$0.65 | +47.45%beat | $213.2MAlpha Vantage | -30.6%from $307.1M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $164.7M | $272.6M | $360.5M | $357.8M |
| Cost of what it sold | $16.3M | $28.0M | $19.9M | $23.7M |
| Gross profit | $148.4M | $244.5M | $340.6M | $334.1M |
| What it spent | ||||
| Research and development | $133.1M | $100.9M | $99.2M | $105.4M |
| Sales and admin | $96.9M | $86.2M | $80.6M | $80.1M |
| Other operating costs | — | $11.6M | $11.8M | $123.6M |
| Total operating expenses | $230.0M | $198.6M | $191.6M | $309.0M |
| What was left | ||||
| Operating profit | -$81.6M | $45.9M | $149.0M | $25.1M |
| Interest on debt | $55.2M | $49.0M | $48.5M | $45.9M |
| Profit before tax | -$139.1M | -$2.5M | $97.5M | -$41.1M |
| Tax | -$4.1M | $347.0K | $14.0M | $10.6M |
| Net profit | -$135.0M | -$2.8M | $83.5M | -$51.7M |
| EBITDA | -$71.0M | $62.0M | $161.9M | $21.6M |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
PTC Therapeutics, Inc. (PTCT) Seasonal Returns Chart - Yahoo Finance
NeutralNov 7PTC Therapeutics (PTCT) Stock Could Be Near Fair Value Today
NeutralNov 5PTC Therapeutics Inc (BH3.SG) Seasonal returns chart - Yahoo Finance
NeutralNov 4Why PTC Therapeutics Bears Were Right Before The Drop
Leans bearishNov 3PTC Therapeutics Authorizes Share Repurchase Program of Up to $500 Million
BullishNov 3PTC Therapeutics to Participate in Upcoming Investor Conferences
NeutralNov 3Citigroup maintains PTC Therapeutics at Buy, raises price target to $109 from $108
BullishNov 2Truist reiterates Hold on PTC Therapeutics stock after Q3 results By Investing.com
NeutralNov 234 macro signals shaping PTCT right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
